# Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

> **NCT04639245** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic Urothelial Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
- **BIOLOGICAL:** PD1 Inhibitor

## Key facts

- **NCT ID:** NCT04639245
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-19
- **Primary completion:** 2022-08-04
- **Final completion:** 2022-08-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2023-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639245, "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04639245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*